The Experts below are selected from a list of 30 Experts worldwide ranked by ideXlab platform
Stéphane Rivet - One of the best experts on this subject based on the ideXlab platform.
-
nevirapine or Lamivudine Plus Stavudine and indinavir examples of 2 class versus 3 class regimens for the treatment of human immunodeficiency virus type 1
Clinical Infectious Diseases, 2002Co-Authors: Odile Launay, Laurence Gérard, Philippe Flandre, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Laurence Morandjoubert, Sonia Guiramandhugon, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.
-
Nevirapine or Lamivudine Plus Stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002Co-Authors: Odile Launay, Laurence Gérard, Laurence Morand-joubert, Philippe Flandre, Sonia Guiramand-hugon, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P
Odile Launay - One of the best experts on this subject based on the ideXlab platform.
-
nevirapine or Lamivudine Plus Stavudine and indinavir examples of 2 class versus 3 class regimens for the treatment of human immunodeficiency virus type 1
Clinical Infectious Diseases, 2002Co-Authors: Odile Launay, Laurence Gérard, Philippe Flandre, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Laurence Morandjoubert, Sonia Guiramandhugon, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.
-
Nevirapine or Lamivudine Plus Stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002Co-Authors: Odile Launay, Laurence Gérard, Laurence Morand-joubert, Philippe Flandre, Sonia Guiramand-hugon, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P
Laurence Gérard - One of the best experts on this subject based on the ideXlab platform.
-
nevirapine or Lamivudine Plus Stavudine and indinavir examples of 2 class versus 3 class regimens for the treatment of human immunodeficiency virus type 1
Clinical Infectious Diseases, 2002Co-Authors: Odile Launay, Laurence Gérard, Philippe Flandre, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Laurence Morandjoubert, Sonia Guiramandhugon, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.
-
Nevirapine or Lamivudine Plus Stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002Co-Authors: Odile Launay, Laurence Gérard, Laurence Morand-joubert, Philippe Flandre, Sonia Guiramand-hugon, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P
Philippe Flandre - One of the best experts on this subject based on the ideXlab platform.
-
nevirapine or Lamivudine Plus Stavudine and indinavir examples of 2 class versus 3 class regimens for the treatment of human immunodeficiency virus type 1
Clinical Infectious Diseases, 2002Co-Authors: Odile Launay, Laurence Gérard, Philippe Flandre, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Laurence Morandjoubert, Sonia Guiramandhugon, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.
-
Nevirapine or Lamivudine Plus Stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002Co-Authors: Odile Launay, Laurence Gérard, Laurence Morand-joubert, Philippe Flandre, Sonia Guiramand-hugon, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P
Véronique Joly - One of the best experts on this subject based on the ideXlab platform.
-
nevirapine or Lamivudine Plus Stavudine and indinavir examples of 2 class versus 3 class regimens for the treatment of human immunodeficiency virus type 1
Clinical Infectious Diseases, 2002Co-Authors: Odile Launay, Laurence Gérard, Philippe Flandre, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Laurence Morandjoubert, Sonia Guiramandhugon, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.
-
Nevirapine or Lamivudine Plus Stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002Co-Authors: Odile Launay, Laurence Gérard, Laurence Morand-joubert, Philippe Flandre, Sonia Guiramand-hugon, Véronique Joly, Gilles Peytavin, Agnàs Certain, Claude Lévy, Stéphane RivetAbstract:We compared use of a 3-class regimen (nevirapine [Nvp], Stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (Lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P
